Description
Cagrilintide 5mg — long-acting amylin analogue for metabolic research in Australia. University-verified ≥99% purity. Same-day Sydney dispatch.
Cagrilintide is a long-acting acylated amylin analogue developed by Novo Nordisk. It activates amylin receptors (AMY1, AMY2, AMY3), which are involved in appetite regulation, gastric emptying, and glucose homeostasis.
What the Research Shows
Research has examined Cagrilintide’s effects on satiety signalling and body weight regulation. The acylation modification extends its half-life, allowing once-weekly dosing in clinical studies.
Phase 2 trials have investigated Cagrilintide alone and in combination with semaglutide. Published data documents effects on appetite, body composition, and metabolic parameters.
Why Australian Researchers Choose Purpose Labs
Every batch is tested at a leading Australian university — HPLC and mass spectrometry confirm ≥99% purity. No generic overseas certificates.
→ Explore the Peptide Research Library
Purity: ≥99% (HPLC)
Form: Lyophilised powder
Molecular Weight: ~3990 Da
Target: Amylin receptors (AMY1/2/3)
Half-life: Extended (acylated)
Research: PubMed
▸ Australian university verified
▸ ≥99% purity guaranteed
▸ Same-day dispatch from Sydney
▸ Research-grade lyophilised powder
Related Research and Resources
For research use only. Not for human consumption.




